PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Attana AB

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Attana Highlighted in Today in America with Terry Bradshaw - Airing on March 5th, nationally in North America on Fox Business Network (4:00 PM ET, 3:00 PM CT, 2:00 PM MT, 1:00 PM PT) and on March 11th on CNN Headline News (Comcast Cable, Seattle- Tacoma, 2:24 pm, 3:24 pm, 5:54 pm, 6:24 pm)
Attana Highlighted in Today in America with Terry Bradshaw

 

NewswireToday - /newswire/ - Stockholm, Sweden, 2011/03/03 - Airing on March 5th, nationally in North America on Fox Business Network (4:00 PM ET, 3:00 PM CT, 2:00 PM MT, 1:00 PM PT) and on March 11th on CNN Headline News (Comcast Cable, Seattle- Tacoma, 2:24 pm, 3:24 pm, 5:54 pm, 6:24 pm).

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Attana AB, developer of biosensors, is proud to announce our participation in Today in America with Terry Bradshaw in their series on topics, trends, and issues related to “Improving Diagnostic Outcomes through Biosensor Technology” as part of the show’s “Medical Minutes” series.

The program aims to inform the general public about the complexities of the human body and to emphasize the challenges of the drug development process. Furthermore, the program presents a solution interesting for scientists and decision makers working within the field of drug development, showing how it is possible to save both time and money when developing drugs. Having access to biologically relevant information, i.e. experimental data that mimics the conditions of the human body as closely as possible is crucial for finding the best new drug candidate. The Attana Cell 200 biosensor has the unique ability to measure molecular interactions directly on human cells and provides critical data to the drug development process.

For every new drug on the market, thousands of candidate molecules have failed during the research and test phases. The later in the process a candidate fails, the more time and money is spent on it. When a candidate reaches the clinical phase with human test subjects, the costs increase significantly. Besides the fact that a faulty drug increases costs, it also has the potential to harm the test persons. Therefore, a drug that is thoroughly investigated before it enters clinical trials risks less harmful consequences.

Attana’s technology provides biologically relevant information that enables selection of the good candidates and sorts out the unsuitable ones earlier in the drug development process. Biologically relevant information is crucial for the drug development process- it helps save both time and money and in finding the best new drug candidate.

For a preview of the show visit our web page at attana.com. If you want to find out more about Attana and our products, send an Email.

The segment will be aired on March 5th, nationally in North America on Fox Business Network (4:00 PM ET, 3:00 PM CT, 2:00 PM MT, 1:00 PM PT) and on March 11th on CNN Headline News (Comcast Cable, Seattle- Tacoma, 2:24 pm, 3:24 pm, 5:54 pm, 6:24 pm). The Today in America program is an independent production hence not a Fox Business Network or CNN Headline News production.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Attana AB

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Attana Highlighted in Today in America with Terry Bradshaw

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Li Huimin - Attana.com 
+46 (0)8 410 200 00 info[.]attana.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Attana AB securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Attana AB / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
ProSci Incorporates Flow Cytometry Screening to Custom Monoclonal Antibody Service
FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors
BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  JobsWare.com

Visit  NAKIVO, Inc.





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)